A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

August 26, 2020

Study Completion Date

August 26, 2020

Conditions
COVID-19
Interventions
DRUG

LY3819253

Administered IV.

DRUG

Placebo

Administered IV.

Trial Locations (11)

10016

Alexandria Center for Life - NYC/ NYCEDC, New York

19140

Temple Univ School of Med, Philadelphia

27514

University of North Carolina, Chapel Hill

27834

Unified Research Enterprise Brody School of Medicine at ECU, Greenville

30322

Emory University, Atlanta

48109

University of Michigan, Ann Arbor

68114

Quality Clinical Research, Inc., Omaha

90048

Cedars Sinai Medical Center, Los Angeles

92161

Veterans Affairs Medical Center San Diego, San Diego

02114

Massachusetts General Hospital, Boston

01655

University of Massachusetts Medical Center, Worcester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AbCellera Biologics Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY